Not medical advice. DrPep does not sell peptides. Educational content only — many compounds are investigational or not FDA-approved. Verify against primary sources and talk with a licensed clinician.

News

FDA actions, compounding debates, and research publications — kept short. Verify against original links. Educational only.

Warnings & compounding

FDA sends “Interim Access Policy” for compounded peptides to White House review

October 14, 2026

HHS/FDA submitted “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94) to OIRA. It is listed as a notice pending review; the text, covered peptides, and conditions are not public. No peptide has been newly approved by this filing alone.

OIRA review listing · Holland & Knight analysis

Research

JAMA Viewpoint warns compounding peptides could undercut FDA drug approval

October 26, 2026

Authors from the Center for Science in the Public Interest (Samantaroy, Xu, Lurie) argue that following the July PCAC votes would expose patients to poorly characterized products and weaken incentives to run approval-level trials.

JAMA Viewpoint

Warnings & compounding

FDA proposes keeping semaglutide, tirzepatide, and liraglutide off the 503B list

April 30, 2026

FDA proposed excluding the three GLP-1 ingredients from the 503B bulks list for outsourcing facilities. Comments closed July 30; no final decision had been posted as of late October 2026.

FDA compounding policy materials